Cytori Therapeutics receives CE Mark in Europe for Intravase Cytori Therapeutics has received a CE Mark in Europe for Intravase, a reagent intended to be used with Cytori’s Celution System for preparing safe and optimized adipose-derived stem and regenerative cells for intravascular delivery into the same patient.
Cytori Therapeutics price target raised to $6 from $3.50 at Roth Capital Roth Capital increased its price target on Cytori after the company received final FDA approval for a clinical trial of its treatment for scleroderma., and the firm attended an event hosted by the company with a scleroderma expert. Roth says that the expert highlighted the unmet medical need in scleroderma as well its significant morbidity and mortality. The firm expects the company's visibility to improve this year, and it keeps a Buy rating on the stock.
Cytori Therapeutics price target raised to $6 from $3.50 at Roth Capital Roth Capital raised its price target for Cytori Therapeutics to $6 and keeps a Buy rating on the name. The stock is rating up 3% to 46c.